Fumihiro Okumura

Gifu-shi, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 75 publications

Pretreatment serum vitamin D levels predict the therapeutic efficacy of atezolizumab plus bevacizumab therapy in advanced hepatocellular carcinoma: a multicenter analysis.

Pretreatment serum vitamin D levels predict the therapeutic efficacy of atezolizumab plus bevacizumab therapy in advanced hepatocellular carcinoma: a multicenter analysis.

Journal: International journal of clinical oncology

Published: February 27, 2026

The Initial Therapeutic Response in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab Contributes to the Change of Liver Function during Treatment: A Multicenter Analysis.

The Initial Therapeutic Response in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab Contributes to the Change of Liver Function during Treatment: A Multicenter Analysis.

Journal: Oncology

Published: February 24, 2026

Determinants of Survival Benefit From Endobiliary Radiofrequency Ablation for Extrahepatic Cholangiocarcinoma According to Tumor Stage, Systemic Therapy, and Session Number.

Determinants of Survival Benefit From Endobiliary Radiofrequency Ablation for Extrahepatic Cholangiocarcinoma According to Tumor Stage, Systemic Therapy, and Session Number.

Journal: Endoscopy international open

Published: February 10, 2026

Bile-Derived Exosomal miR-196a/-196b as Diagnostic Biomarkers Associated With Tumor Progression in Biliary Tract Cancer.

Bile-Derived Exosomal miR-196a/-196b as Diagnostic Biomarkers Associated With Tumor Progression in Biliary Tract Cancer.

Journal: Cancer science

Published: December 24, 2025

Suprapapillary stent-by-stent deployment using slim fully covered metal stents versus plastic stents for unresectable malignant hilar biliary obstruction (SBSFLUX Trial): protocol for a multicenter randomized controlled trial.

Suprapapillary stent-by-stent deployment using slim fully covered metal stents versus plastic stents for unresectable malignant hilar biliary obstruction (SBSFLUX Trial): protocol for a multicenter randomized controlled trial.

Journal: Trials

Published: October 10, 2025

Endoscopic Stenting for Unresectable Malignant Hilar Biliary Obstruction: Where Do We Stand Today? A Narrative Review.

Endoscopic Stenting for Unresectable Malignant Hilar Biliary Obstruction: Where Do We Stand Today? A Narrative Review.

Journal: Current oncology (Toronto, Ont.)

Published: September 30, 2025

Clinicopathological features of localized-type IgG4-related cholecystitis: a nationwide multicenter study in Japan.

Clinicopathological features of localized-type IgG4-related cholecystitis: a nationwide multicenter study in Japan.

Journal: Journal of gastroenterology

Published: September 02, 2025

The Low Platelet Count at the Start of Atezolizumab Plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma Predicts Deteriorated Liver Function at the Time of Disease Progression Thereafter: A Multicenter Analysis.

The Low Platelet Count at the Start of Atezolizumab Plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma Predicts Deteriorated Liver Function at the Time of Disease Progression Thereafter: A Multicenter Analysis.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: August 19, 2025

Suprapapillary Stent-By-Stent Deployment With Slim-Fully Covered Versus Uncovered Metal Stents for Malignant Hilar Biliary Obstruction: A Multicenter Comparative Study (With Video).

Suprapapillary Stent-By-Stent Deployment With Slim-Fully Covered Versus Uncovered Metal Stents for Malignant Hilar Biliary Obstruction: A Multicenter Comparative Study (With Video).

Journal: Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society

Published: May 26, 2025

The Neutrophil-to-Lymphocyte Ratio during Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma Predicts Long-Term Therapeutic Efficacy: A Multicenter Analysis.

The Neutrophil-to-Lymphocyte Ratio during Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma Predicts Long-Term Therapeutic Efficacy: A Multicenter Analysis.

Journal: Oncology

Published: April 27, 2025

Intra-stent Radiofrequency Ablation Versus Plastic Stent Placement for Ingrowth Occlusion After Bilateral Metal Stenting in Patients with Malignant Hilar Biliary Obstruction: A Multicenter Propensity Score-Matched Analysis.

Intra-stent Radiofrequency Ablation Versus Plastic Stent Placement for Ingrowth Occlusion After Bilateral Metal Stenting in Patients with Malignant Hilar Biliary Obstruction: A Multicenter Propensity Score-Matched Analysis.

Journal: Digestive diseases and sciences

Published: April 15, 2025

Number of Tumors Stratifies the Therapeutic Response to Atezolizumab plus Bevacizumab Therapy in Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: A Multicenter Analysis.

Number of Tumors Stratifies the Therapeutic Response to Atezolizumab plus Bevacizumab Therapy in Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: A Multicenter Analysis.

Journal: Oncology

Published: February 10, 2025

Showing 1-12 of 75

Last Updated: 09/26/2026